New drug duo aims to halt deadly blood cancer progression
NCT ID NCT05074355
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This study tests whether combining two drugs, venetoclax and azacitidine, is safe and effective for people with a rare, advanced blood cancer called myeloproliferative neoplasm (MPN) that has worsened. About 40 participants will receive the combination therapy. The goal is to see if the treatment can bring the cancer back to a less aggressive stage or achieve remission.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACCELERATED PHASE BCR-ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2M9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug reduce bloodletting for polycythemia vera?
- Could a walk a day keep brain fog away after a stem cell transplant?
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a modified interferon rein in early myelofibrosis?
- Can pressurized oxygen boost cord blood transplants?
- New transplant recipe aims to tame Graft-Versus-Host disease